GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$9.25
-0.04 (-0.43%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
24d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GRFS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: GRFS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.76
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.03
16.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $9.25, which is considered slightly high relative to its 30-day fair value range of $8.94 to $9.33. The stock's valuation (Forward PE: 7.1) is in line with its historical norms (7.0). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GRFS is in a downtrend. The price is approaching resistance at $9.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GRFS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.53 (+34.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GRFS is in a downtrend. The price is approaching resistance at $9.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GRFS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.53 (+34.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$8.94 -
$9.33
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.8% below Wall St target ($12.53)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$8.94 -
$9.33
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.63
Resistance Level
$9.41
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
7.13
Wall Street Target
$12.53
(+34.8%)
Revenue Growth (YoY)
4.0%
Earnings Growth (YoY)
750.0%
Profit Margin
5.0%
Valuation Premium vs History
+0.5% premium
PE vs Historical
7.1 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.5%
(market-implied from PE analysis)
1-Year Target
$9.34
(+1%)
2-Year Target
$9.38
(+1%)
3-Year Target
$9.43
(+2%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$9.26
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 49.4%)
$96.93
(+943%)
Base:
(SPY PE: 7.1, Growth: 49.4%)
$31.00
(+234%)
Bear:
(PE: 6.1, Growth: 49.4%)
$26.35
(+184%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 13.81 | Current EPS (TTM): $0.63
Bull Case
$19.14
(+107%)
Analyst growth 100.0%, PE expands to 15.2
Base Case
$17.40
(+88%)
Market implied 100.0%, PE stable at 13.8
Bear Case
$5.92
(-36%)
Severe decline -20.0%, PE contracts to 11.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 11:58 PM ET
Data refreshes hourly during market hours. Next update: 12:58 AM
Data refreshes hourly during market hours. Next update: 12:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced GRFS Option Strategies
Professional options setups generated by AI based on today's GRFS price and gamma walls.
